Navigation Links
Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer
Date:4/16/2012

EXTON, Pa., April 16, 2012 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 in the treatment of metastatic colorectal cancer that is refractory to all standard therapy. MORAb-004 is a monoclonal antibody that specifically binds to endosialin/tumor endothelial marker-1 (TEM-1).

The trial is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of single agent MORAb-004 plus best supportive care as determined by progression-free survival in patients with chemorefractory metastatic colorectal cancer. Secondary objectives include assessment of an overall survival benefit, identification of biomarkers to predict efficacy, and safety of single agent MORAb-004.

Morphotek expects to enroll up to 160 patients in this study, which is being conducted at clinical centers in the United States.  As part of the trial, patient tumors and plasma samples will be tested for endosialin/TEM-1 and/or proteins within its pathway to determine if the pattern of expression relates to or determines clinical effect. The goal of these investigations is to identify those patients who had a clinically meaningful response to MORAb-004.

"We are excited to have initiated this Phase II study of MORAb-004 in metastatic colorectal cancer," stated Christina Coughlin, M.D., Ph.D., Senior Director of Clinical Development at Morphotek. "New agents are needed for the treatment of metastatic colorectal cancer.  The treatment of chemorefractory colorectal cancer remains an area of significant unmet medical need in the field of oncology. We are pleased to have the opportunity to collaborate with several key experts in this disease setting."

MORAb-004 is a humanized monoclonal antibody specific for endosialin/TEM-1 protein.  The target is found to be expressed on the cell surface of cells call
'/>"/>

SOURCE Morphotek(R), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc.
2. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... ST. PAUL, Minn. , March 6, 2015 /PRNewswire/ ... benefit manager serving more than 26 million members, today ... and Drug Administration,s (FDA) approval of the first biosimilar ... U.S. Food and Drug Administration (FDA) approval of Sandoz,s ... of all cancer patients, is a major milestone in ...
(Date:3/6/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... for the fourth quarter and year ended December 31, ... or less than $0.01 per share, on revenues of ... compares with net income of $195,000, or $0.01 per ... of 2013. The substantial increase in fourth quarter 2014 ...
(Date:3/6/2015)... Ultra Clean Systems, Inc. ... manufacturer of da Vinci® robotic surgical ... approval reflects the unit,s ability to perform at ... for the sterile processing industry. Few companies have ... instruments for re-use. Ultra Clean Systems ...
Breaking Medicine Technology:Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 2Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 2Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 4Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 5Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications 2
... ... ... ... ...
... ... ... , ... ...
Cached Medicine Technology:An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 2An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 3An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 4An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 5An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 6Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease 2Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease 3Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease 4Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease 5
(Date:3/6/2015)... 06, 2015 Johnson & Johnson and ... on March 5, 2015 in Superior Court in the ... documents, a jury of 12 awarded Mrs. Perry $700,000 ... implanted with an Ethicon TVT Abbrevo plastic sling for ... three women also awarded $5 million in punitive damages. ...
(Date:3/6/2015)... Many patients with knee osteoarthritis have ... you (or someone you know) have chronic pain and ... be interested in the ACT-OA clinical trial. , ... he is one of fifteen physicians in the U.S. ... subjects as part of a new, multi-site, double blind, ...
(Date:3/6/2015)... Truly Nolen, the largest family-owned pest control ... opening of their first independently-owned and operated franchise in ... Fort Mill – Rock Hill, SC area. The ribbon ... their new location. , The Truly Nolen ... in the pest control industry. Locally owned and operated ...
(Date:3/6/2015)... Yisrayl Hawkins, Pastor and Overseer of The House ... publication explaining how micro-kingdoms keep the earth and everything ... “Microorganisms Do Much More Than You Think” is a ... and designed to keep all things functioning properly. He ... of these micro-kingdom, but does not realize their full ...
(Date:3/6/2015)... FCPX developers have announced a ... , “Pro3rd Hue is a lower 3rd pack with a ... Film Studios. “Blurring the line between professional and armature, Pro3rd ... a set of 30 customizable lower third presets made exclusively ... FCPX users can complement any design with a clean and ...
Breaking Medicine News(10 mins):Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Kevin Darr, M.D. is Now Enrolling Patients in a New FDA-Approved Clinical Trial Evaluating Adipose-Derived Regenerative Cells in the Treatment of Knee Osteoarthritis 2Health News:First Truly Nolen Franchise Opening in North Carolina 2Health News:Yisrayl Hawkins Tells Scientists Exactly What Makes Life Function Properly in New Publication 2Health News:A New Plugin Entitled Pro3rd Hue was Released Today from Pixel Film Studios Exclusively for FCPX 2
... may underlie the worrisome numbers, researchers say , TUESDAY, May ... care facilities may have a higher rate of suicide than ... new report. , People over 65 commit suicide at ... a study of Italian people living in long-term care facilities, ...
... , TUESDAY, May 18 (HealthDay News) -- Intense exercise ... other symptoms typically associated with asthma in children who ... findings -- based on an analysis of 56 healthy ... on prior research that suggested that adults can similarly ...
... Profiles created for physicians based on the cost of the ... used by insurance companies to create the profiles, according to ... add to the concern about the accuracy of physician cost ... to encourage patients to visit low-cost physicians. "This study ...
... ... Burrill, Funder and Supporter of Biotech industry, Kevin Hrusovsky, CEO Caliper Life Science, and More ... Boston, MA (PRWEB) May ... the healthcare, education and energy industries, and LabRoots , a free social networking site ...
... Counting calories ... Stacey Rosenfeld , ... York, NY (Vocus) -- With the incidence of disordered eating continuing to rise among children, ... eating disorder or have a poor body image, says New York City-based psychologist and eating ...
... products tested, group calls for federal ban , TUESDAY, ... chemical used in the metal linings of some canned foods, ... banned, a new report claims. , BPA is ubiquitous in ... it has come under scrutiny in recent years, with studies ...
Cached Medicine News:Health News:Suicide Risk May Be Higher in Senior Facilities 2Health News:Suicide Risk May Be Higher in Senior Facilities 3Health News:Exercise Can Spur Wheezing, Even in Healthy Kids 2Health News:Results of physician cost profiling can vary widely, study finds 2Health News:BioConference Live Announces Speakers and Sponsors for Second Edition of Premier Online Conference for Life Science Community 2Health News:BioConference Live Announces Speakers and Sponsors for Second Edition of Premier Online Conference for Life Science Community 3Health News:BioConference Live Announces Speakers and Sponsors for Second Edition of Premier Online Conference for Life Science Community 4Health News:Dr. Stacey Rosenfeld Offers Tips on How to Raise a Child who has Body Confidence and a Healthy Relationship with Food 2Health News:Dr. Stacey Rosenfeld Offers Tips on How to Raise a Child who has Body Confidence and a Healthy Relationship with Food 3Health News:BPA in Cans Poses Health Threat, Report Claims 2Health News:BPA in Cans Poses Health Threat, Report Claims 3Health News:BPA in Cans Poses Health Threat, Report Claims 4
... system is ideal for the physician who ... a broad base of clinical applications. The ... performance in the treaent of deeper lying ... complement for vascular and pigmented lesions, including ...
Available in Purple, orange, dark blue, yellow, gray, royal blue, green and light blue colors....
Icefire has ice crystals on the top of a cool blue iris....
This pattern transform your pupils into narrow slits surrounded by eye stopping yellow. Works well with kitty-cat costumes....
Medicine Products: